| Orginal Article |
|
|
|
|
| TAEST16001:TCR Affinity Enhanced Specific-T-cell Therapy |
Yu-sheng OU,Hong-jun ZHENG,Shi ZHONG,Yi LI( ) |
| Guangdong Xiangxue Life Sciences Ltd. Guangzhou 510663, China |
|
|
|
Abstract The illustration of human immune system has been substantially clearer than 20 years ago with the credit of a vast amount of comprehensive studies for decades. In particular, its role in tumor development has attracted unprecedented attention. It has been found that the molecules of the immune system can be utilized very effectively to control cancer development and even cure cancer completely. At the early days, this phenomenon was only sporadically spread in professional circles, but since cancer immunotherapy became the winner of Science’s top ten breakthroughs of the year in 2013, publics have been constantly refreshed by the results of immunotherapy. The climax of this phenomenon is reflected in the 2018 Nobel Prize judges who were unable to hold on their usual cautious and awarded the Medical and Physiology Award to two immunologists in recognition of their discovery of the regulatory mechanism of two important immune molecules, PD-1 and CTLA-4, since antibodies targeting these two molecules show predictable effects in tumor immunotherapy. A further affirmation is that half of the Nobel Prize in Chemistry of the same year was awarded to the inventors of phage-display technology for generation of antibodies. Therefore, immunotherapy has become an important approach of cancer treatment, and it has become an indisputable fact that it is listed as the fourth treatment mode after surgery, radiotherapy and chemotherapy. Tumor immunotherapy can be achieved by biologics or by immune cells. The latter is to modify and expand the relevant immune cells by cell engineering technology, and then infuse the cells to the corresponding patients to enhance the patient’s anti-tumor immunity, and ultimately achieve the purpose of eliminating tumor cells. In this paper, the concepts of T-cell immunotherapy and the current development of its application are briefly described. In addition, the first clinic stage product TAEST16001 and the companion diagnostic kits of Guangdong Xiangxue Life Sciences Ltd., a subsidiary of Xiangxue Group, has been briefly presented.
|
|
Received: 10 January 2019
Published: 26 March 2019
|
|
|
| Fund: FoundationOne CDx;FoundationFocus CDxBRCA Assay |
|
|
| [1] |
Robbins P F, El-Gamil M, Li Y F , et al. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. The Journal of Immunology, 2002,169(10):6036-6047.
doi: 10.4049/jimmunol.169.10.6036
pmid: 12421991
|
|
|
| [2] |
Fesnak A D, June C H, Levine B L . Engineered T cells: the promise and challenges of cancer immunotherapy. Nature Reviews. Cancer, 2016,16(9):566-581.
doi: 10.1038/nrc.2016.97
pmid: 27550819
|
|
|
| [3] |
Van Schandevyl S, Kerre T . Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. Acta Clinica Belgica, 2018: 1-7.
doi: 10.1080/17843286.2018.1545373
|
|
|
| [4] |
Tammana S, Huang X, Wong M , et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Human Gene Therapy, 2010,21(1):75-86.
doi: 10.1089/hum.2009.122
pmid: 19719389
|
|
|
| [5] |
Zhang H, Snyder K M, Suhoski M M , et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. Journal of Immunology, 2007,179(7):4910-4918.
doi: 10.4049/jimmunol.179.7.4910
pmid: 17878391
|
|
|
| [6] |
Morgan R A, Yang J C, Kitano M , et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 2010,18(4):843-851.
doi: 10.1038/mt.2010.24
pmid: 20179677
|
|
|
| [7] |
Rosenberg S A, Kochenderfer J N . Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers. Molecular Therapy: The Journal of the American Society of Gene Therapy, 2011,19(11):1928-1930.
doi: 10.1038/mt.2011.223
pmid: 22051601
|
|
|
| [8] |
Porter D L, Levine B L, Kalos M , et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 2011,365(8):725-733.
doi: 10.1056/NEJMoa1103849
|
|
|
| [9] |
Mueller K T, Maude S L, Porter D L , et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017,130(21):2317-2325.
doi: 10.1182/blood-2017-06-786129
pmid: 28935694
|
|
|
| [10] |
Morgan R A, Dudley M E, Wunderlich J R , et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 2006,314(5796):126-129.
doi: 10.1126/science.1129003
|
|
|
| [11] |
Holler P D, Holman P O, Shusta E V , et al. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proceedings of the National Academy of Sciences of the United States of America, 2000,97(10):5387-5392.
doi: 10.1073/pnas.080078297
pmid: 10779548
|
|
|
| [12] |
Tan M P, Gerry A B, Brewer J E , et al. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clinical and Experimental Immunology, 2015,180(2):255-270.
doi: 10.1111/cei.12570
|
|
|
| [13] |
Zhong S, Malecek K, Johnson L A , et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2013,110(17):6973-6978.
doi: 10.1073/pnas.1221609110
pmid: 23576742
|
|
|
| [14] |
Hay K A . Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. British Journal of Haematology, 2018,183(3):364-374.
doi: 10.1111/bjh.2018.183.issue-3
|
|
|
| [15] |
Xu J, Wang Q, Xu H , et al. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. Journal of Hematology & Oncology, 2018,11(1):128.
doi: 10.1186/s13045-018-0672-7
|
|
|
| [16] |
Shalabi H, Wolters P L, Martin S , et al. Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-Cell therapy. Journal of Immunotherapy, 2018,41(7):350-358.
doi: 10.1097/CJI.0000000000000241
pmid: 30048343
|
|
|
| [17] |
Stauss H J, Morris E C, Abken H . Cancer gene therapy with T cell receptors and chimeric antigen receptors. Current Opinion in Pharmacology, 2015,24:113-118.
doi: 10.1016/j.coph.2015.08.006
pmid: 26342910
|
|
|
| [18] |
Hunder N N, Wallen H, Cao J , et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. The New England Journal of Medicine, 2008,358(25):2698-2703.
doi: 10.1056/NEJMoa0800251
|
|
|
| [19] |
Johnson L A, Morgan R A, Dudley M E , et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009,114(3):535-546.
doi: 10.1182/blood-2009-03-211714
pmid: 19451549
|
|
|
| [20] |
Robbins P F, Morgan R A, Feldman S A , et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology, 2011,29(7):917-924.
doi: 10.1200/JCO.2010.32.2537
pmid: 21282551
|
|
|
| [21] |
Robbins P F, Kassim S H , Tran T L N, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research, 2015,21(5):1019-1027.
doi: 10.1158/1078-0432.CCR-14-2708
|
|
|
| [22] |
Rapoport A P, Stadtmauer E A , Binder-Scholl G K, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 2015,21(8):914-921.
doi: 10.1038/nm.3910
pmid: 26193344
|
|
|
| [23] |
Li Y, Moysey R, Molloy P E, Vuidepot A-L , et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nature Biotechnology, 2005,23(3):349-354.
doi: 10.1038/nbt1070
pmid: 15723046
|
|
|
| [24] |
Krishnadas D K, Bai F, Lucas K G . Cancer testis antigen and immunotherapy. Immuno Targets and Therapy, 2013,2:11-19.
doi: 10.2147/ITT.S35570
pmid: 27471684
|
|
|
| [25] |
Sarcoma Committee of China Anti-Cancer Association, Chinese Society of Clinical Oncology. Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas Version 2015. Chinese Journal of Oncology, 2016,38(4):310-320.
doi: 10.3760/cma.j.issn.0253-3766.2016.04.013
pmid: 27087380
|
|
|
| [26] |
Yang L, Fang Z W, Fan Z F , et al. An analysis of incidence trends and characteristics of soft tissue sarcoma in Beijing, 1999-2013. Chinese Journal of Oncology, 2017,39(6):471-476.
doi: 10.3760/cma.j.issn.0253-3766.2017.06.013
pmid: 28635239
|
|
|
| [27] |
J?rgensen J T . The importance of predictive biomarkers in oncology drug development. Expert Review of Molecular Diagnostics, 2016,16(8):807-809.
doi: 10.1080/14737159.2016.1199962
pmid: 27282189
|
|
|
| [28] |
Papadopoulos N, Kinzler K W, Vogelstein B . The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology, 2006,24(8):985-995.
doi: 10.1038/nbt1234
pmid: 16900147
|
|
|
| [29] |
Roscoe D M, Hu Y-F, Philip R . Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals. Expert Review of Molecular Diagnostics, 2015,15(7):869-880.
doi: 10.1586/14737159.2015.1045490
pmid: 26109316
|
|
|
| [30] |
Nagai S, Urata M, Sato H , et al. Evolving Japanese regulations on companion diagnostics. Nature Biotechnology, 2016,34:141-144.
doi: 10.1038/nbt.3478
pmid: 26849515
|
|
|
| [31] |
Enzmann H, Meyer R, Broich K . The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics. Biomarkers in Medicine, 2016,10(12):1261-1268.
doi: 10.2217/bmm-2016-0233
pmid: 27661101
|
|
|
| [32] |
J?rgensen J T, Hersom M . Companion diagnostics-a tool to improve pharmacotherapy. Annals of Translational Medicine, 2016,4(24):482.
doi: 10.21037/atm.2016.12.26
pmid: 28149844
|
|
|
| [33] |
J?rgensen J T, Winther H. The development of the HercepTest - from bench to bedside//Molecular Diagnostics-The Key Driver of Personalized Cancer Medicine. Singapore: Pan Stanford Publishing Pte. Ltd., 2010: 43-60.
|
|
|
| [34] |
FDA. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). [2019-01-04]..
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
